Tharimmune (THAR) Appoints Clay Kahler and Gary Stetz to its Board

Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing the Tharimmune Board to nine Directors. As reported in a Form 8-K filed on April 25, 2025, Directors Leonard Mazur and Lynne Bui, M.D. have notified the Board that they will not seek re-election at the Company's 2025 Annual Meeting of Stockholders on June 10, at which time the size of the Board will decline to seven Directors.

Messrs. Kahler and Stetz bring deep leadership, operational, financial and strategic expertise to the Board as Tharimmune advances key clinical programs, executes on growth initiatives and strengthens corporate governance. Mr. Kahler will serve on the audit and nominating and corporate governance committees and chair the compensation committee and Mr. Stetz will serve on the compensation and audit committees and chair the nominating and corporate governance committee.

"On behalf of the Board, we are pleased to welcome Clay and Gary to the Tharimmune Board as we continue to execute on our growth strategy," said Randy Milby, Chairman of the Board of Tharimmune. "Clay's entrepreneurial leadership and deep operational expertise in life sciences manufacturing and clinical innovation, combined with Gary's extensive financial acumen and governance experience will bring valuable insight to our Board. We look forward to their contributions as we advance our product pipeline and build shareholder value."

Clay Kahler is a seasoned entrepreneur with decades of leadership experience in life sciences, biotechnology, and technology ventures. He is the Co-founder, CEO, and Managing Director of Spray Labs, LLC, an FDA-registered, cGMP-certified manufacturer specializing in oral spray drug delivery technologies. He is also the Founder and CEO of Gateway Sciences LLC, a company focused on regenerative medicine and mental health. Mr. Kahler co-founded Helius Medical Technologies, Inc., where he played a pivotal role in structuring early corporate financing, facilitating the company's public listing, and establishing strategic partnerships including worked with the team to secure a multi-million dollar Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense, through the U.S. Army Medical Research and Materiel Command (USAMRMC). These efforts helped propel the company to a peak market capitalization of approximately $500 million. He has also held multiple corporate advisory positions including UK-based Velocity Mobile Limited, doing business as Velocity Black, which was successfully acquired by Capital One Financial Corporation in June 2023 for approximately $300 million.

Gary Stetz is a seasoned financial executive with over 35 years of experience across accounting, finance, business valuation and corporate governance. Mr. Stetz currently serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm with more than 1,000 corporate clients. His extensive leadership experience includes founding Allegiance Community Bank and serving on the Board of BCB Bancorp. He is co-author of the book Project Management Accounting. Mr. Stetz's extensive expertise in financial forensics, valuation, and regulatory compliance will provide valuable oversight as Tharimmune continues to build a strong financial and operational foundation.

"I am honored to join the Tharimmune Board and contribute my experience in public company leadership, clinical development and strategic growth initiatives," said Mr. Kahler. "Tharimmune's novel approach to treating immune-mediated diseases is compelling and holds great clinical promise, and I look forward to supporting the Company's future success."

"I am excited to work alongside the talented team at Tharimmune and leveraging my financial, advisory and governance experience to guide the Company during this important phase of growth," added Mr. Stetz. "I look forward to supporting executive management to achieve Tharimmune's strategic and operational goals."

The appointments of Mr. Stetz and Mr. Kahler underscore Tharimmune's commitment to assembling a diverse and accomplished Board, equipped to guide the Company through its next phases of clinical progress, regulatory engagement, and strategic growth.

You May Also Be Interested In

• US Eyes 7.5% China Overcapacity Tariffs Before Xi-Trump Talks - Bloomberg
• ZoomInfo updates its MCP integration on Salesforce's AgentExchange
• US Tiger Securities Reiterates Hold Rating on Pinduoduo Inc. (PDD)